Form 4 for TNGX Tango Therapeutics, Inc.
Accepted 2026-04-02 20:09:07 ET · period of report 2026-04-01 · accession 0001193125-26-140874 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-02 20:09 | 2026-04-01 | TNGX | Crystal Adam | Pres, R, D | M - OptEx | $5.20 | +27.0K | 139.6K | +24% | +$140.4K |
| DT | 2026-04-02 20:09 | 2026-04-01 | TNGX | Crystal Adam | Pres, R, D | S - Sale+OE | $21.20 | -27.0K | 112.6K | -19% | -$572.5K |
| DT | 2026-04-02 20:09 | 2026-04-01 | TNGX | Crystal Adam | Pres, R, D | M - OptEx | $0.00 | -27.0K | 433.5K | -6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-01 | M | A | 27,000 | $5.20 | 139,622 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. |
| 2 | Common | Common Stock | 2026-04-01 | S | D | 27,000 | $21.20 | 112,622 | D | — | — | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-04-01 | M | D | 27,000 | $0.00 | 433,500 | D | $5.20 · — to 2033-03-01 | 27,000 Common Stock | (F1) These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025. (F3) This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter. |